SAB Biotherapeutics (SABS) Stock Statistics & Valuation Metrics

SAB Biotherapeutics has a market cap or net worth of $33.84M. The enterprise value is $17.02M.

SAB Biotherapeutics has 10,411,061 shares outstanding. The number of shares has decreased by -2.65% in one year.

SAB Biotherapeutics’s return on equity (ROE) is -1.31 and return on invested capital (ROIC) is -115.89%.

The current PE Ratio of SAB Biotherapeutics is ―. SAB Biotherapeutics’s PEG ratio is 0.02.

In the last 12 months, SAB Biotherapeutics had revenue of 1.32M and earned -34.11M in profits. Earnings per share was -3.68.

In the last 12 months, operating cash flow was -37.27M and capital expenditures -55.38K, giving a free cash flow of -37.33M billion.

SAB Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

SAB Biotherapeutics upcoming earnings date is Mar 26, 2026, During Market Hours (Confirmed).

SAB Biotherapeutics as a current ratio of 2.98, with Debt / Equity ratio of 3.75%

In the past 12 months, SAB Biotherapeutics has paid 0.00 in taxes.

SAB Biotherapeutics EV to EBITDA ratio is -1.06, with an EV/FCF ratio of -0.89.

SAB Biotherapeutics has $110.88M in cash and marketable securities with $6.19M in debt, giving a net cash position of $104.69M billion.

Gross margin is 0.00%, with operating margin of -3245.92%, and net profit margin of -2579.80%.

The average price target for SAB Biotherapeutics is $8.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy